Target Discovery & Validation Services
Background Workflow Featured Services Publication Why Choose Us FAQs Customer Review Related Services Contact Us
Precision Target Discovery: Fueling Drug Innovation
Target discovery and validation are key steps in drug discovery; however, finding proper targets in related pathways can be challenging. Combining genomics/genome sequencing platform with sophisticated cell analysis, Creative Biolabs can quickly identify targets in virtually any biological matrix, nominally cell cultures, tissues, or body fluids. Our target discovery services can help researchers who are practicing in the field, such as breast cancer, melanoma, lung cancer, sarcomas, hematologic malignancies, and others.
You are likely to benefit if you are looking to:
-
Identify a therapeutic agent for a particular disease or condition that does not have a treatment currently.
-
Discover or validate drug targets that may be novel, presumed, or identified at this stage.
-
Discover or validate new high-quality targets for common protein targets, including enzymes, cell signaling receptors, structural proteins, and regulatory factors such as protein kinases.
-
Finding other emerging targets includes nucleic acids such as mRNA, lipids, and carbohydrates.
Workflow: From Concept to Confirmed Target
Required Starting Materials:
To initiate your project with Creative Biolabs, clients typically need to provide:
-
Disease-specific biological samples.
-
Preliminary genetic or phenotypic data.
-
Specific research objectives or hypotheses.
Key Steps Involved:
Final Deliverables:
-
Comprehensive project.
-
Prioritized therapeutic targets.
-
Strategic recommendations.
One-stop Target Discovery and Validation Services
Creative Biolabs has developed an innovative phenotypic screening platform to update on technology portfolio we currently serve. In the target-based screening, we are able to validate candidate targets by combining a number of experimental methods, such as high-content screening, high-throughput gene expression analysis, human primary cell-based assays, and others. Using our AI-related systems, we can further validate the functions of disease targets and, hopefully, explain how the target modulations possess therapeutic effects.
Genome Sequencing
Creative Biolabs, a leading oncology next-generation sequencing provider, specializes in cancer genomics and bioinformatics. We offer complete, precise whole genome analysis solutions, from sampling to reporting, delivering high-quality insights for cancer research and treatment.
Learn More →
Gene Expression Profiling
Creative Biolabs offers comprehensive gene expression profiling, utilizing expertise in molecular biology, genetics, and bioinformatics. We apply advanced techniques like microarrays and transcriptomics sequencing, providing customized solutions tailored for accurate, high-quality results to meet client research goals.
Learn More →
Target Genome Editing
Creative Biolabs leads in target genome editing, utilizing advanced CRISPR-based systems for precise DNA modifications. This enables gene modulation, therapeutic target screening, and studying genomic alterations, accelerating research from discovery to therapeutic development.
Learn More →
High Content Screening
Creative Biolabs leverages innovative high-content screening technology, creating customized assays for rigorous scientific research. With expertise in bioinformatics, disease biology, and image analysis, we provide robust, scalable high-content screening data to clients worldwide.
Learn More →
Structure Determination
Creative Biolabs offers structural determination services using cutting-edge methods. This vital step in drug discovery obtains 3D molecular structures, enabling topological mapping and mode of action studies to optimize efficacy and selectivity, facilitating structural biology research.
Learn More →
Contact Our Team for More Information and to Discuss Your Project.
Publication
This publication is a comprehensive review exploring how human genetic evidence, particularly beneficial loss-of-function (LOF) mutations, is accelerating drug discovery. It details the structure, molecular biology, and drug development of eight key LOF mutation targets (PCSK9, ANGPTL3, ASGR1, HSD17B13, KHK, CIDEB, and INHBE), highlighting their feasibility for drug development and discussing research prospects. The review emphasizes that drugs supported by human genetic data, identified through technologies like GWAS, WES, and WGS, are more likely to achieve faster clinical trial success and market approval.
Fig.1 Drug discovery driven by favorable loss-of-function genetic variants.1
Why Choose Us?
Creative Biolabs stands at the forefront of target discovery and validation, distinguished by our unparalleled expertise, fully integrated platforms, and unwavering commitment to client success. Our unique advantages are designed to provide you with a competitive edge:
Human Genetics-First Approach
We focus on targets backed by strong human genetic evidence, like beneficial loss-of-function mutations. This strategy, proven by PCSK9 and ANGPTL3 inhibitors, boosts the likelihood of clinical success by using natural human disease resistance, thereby reducing pipeline risks and speeding up drug development.
Integrated Multi-Omics Capabilities
Our extensive genomics, proteomics, and metabolomics services provide a complete view of disease biology. This integrated approach allows for more precise target selection and validation, revealing complex biological connections.
Cutting-Edge Functional Validation Tools
Creative Biolabs provides advanced tools such as CRISPR-based genome editing for direct gene manipulation, High-content screening (HCS) for phenotypic analysis, and advanced structural biology for molecular insights. These tools are used to validate the target's functionality and clarify its mechanisms.
Experienced Scientific Team
Our senior scientists have over two decades of combined experience across various disciplines, offering deep scientific knowledge and excellent problem-solving skills to every project. This guarantees innovative and robust solutions and consistently successful results.
FAQs
Q1: How does Creative Biolabs ensure the novelty of identified targets?
A1: We employ a multi-faceted approach to ensure the novelty of identified targets. This combines extensive bioinformatics analysis of vast public and proprietary databases with our cutting-edge human genetics-driven discovery platforms. This rigorous process allows us to identify novel associations and unique target characteristics, clearly differentiating them from existing knowledge.
Q2: What types of diseases can your target discovery and validation services address?
A2: Our services are highly versatile and applicable across a broad spectrum of disease areas. This includes various cancers (such as breast cancer, melanoma, lung cancer, sarcomas, and hematologic malignancies), complex metabolic disorders, neurodegenerative diseases, and infectious diseases. We meticulously tailor our strategies to the specific biological context and unique challenges of your project.
Q3: Can Creative Biolabs assist with targets beyond proteins, such as nucleic acids or lipids?
A3: Absolutely! While proteins are indeed common therapeutic targets, Creative Biolabs' capabilities extend comprehensively to other emerging target classes, including crucial nucleic acids (such as mRNA), various lipids, and complex carbohydrates. Our diverse expertise, combined with advanced analytical platforms, enables us to effectively identify and validate a wide range of biomolecules highly relevant to disease pathogenesis.
Customer Review
-
Breakthrough Insight
Using Creative Biolabs' target discovery and validation in our research has significantly improved our understanding of disease causality. Their multi-omics approach revealed unexpected pathways, leading us to a highly promising novel target we wouldn't have found otherwise. This insight was invaluable. - Dr. A***n S
-
Reliable Data
Creative Biolabs' in vitro safety assessment for our newly identified target provided rapid and reliable toxicity profiles. This early data allowed us to make informed decisions and pivot our strategy effectively, preventing costly late-stage failures. Their rigorous approach instills great confidence. - Prof. F***k R
Related Services
To further support and streamline your drug discovery and development journey, Creative Biolabs offers a comprehensive suite of complementary services designed to integrate seamlessly with our target discovery and validation offerings:
Biologics Testing
Creative Biolabs offers comprehensive, customized biologics testing services throughout drug development. Their biological/potency assays are developed, optimized, validated, and performed under regulations, following international guidelines.
Learn More →
Protein Binding Analysis Service
Creative Biolabs has extensive experience in protein binding studies, offering advice and support from sample preparation to data analysis. They provide various protein binding assays and will recommend the most suitable approach to ensure accurate and reproducible results for informed decisions about drug candidates.
Learn More →
Contact Us
Ready to accelerate your drug discovery project with unparalleled precision? Contact our expert team today to discuss your specific needs and learn how Creative Biolabs can be your trusted partner in target discovery and validation. We are here to support your success.
Please feel free to contact us for more detailed information.
Reference
-
Zhang, Xiaoxia, et al. "Drug development advances in human genetics‐based targets." MedComm 5.2 (2024): e481. Distributed under Open Access license CC BY 4.0, without modification. DOI: https://doi.org/10.1002/mco2.481
